Activation of TLR9-dependent p38MAPK pathway in the pathogenesis of primary Sjögren's syndrome in NOD/Ltj mouse

Journal of Oral Pathology and Medicine

Volumn 43, Issue 10, 2014, Pages 785-791

  Shi, Huan ^a   Yu, Chuang Qi ^a   Xie, Li Song ^a   Wang, Zhi Jun ^a   Zhang, Ping ^a   Zheng, Ling Yan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Flow cytometry; NOD Ltj; P38 MAPK; Sj gren's syndrome; TLR9

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; TOLL LIKE RECEPTOR 9; TLR9 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; SALIVATION; SJOEGREN SYNDROME; SUBMANDIBULAR GLAND; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; COMPARATIVE STUDY; DISEASE MODEL; ENZYMOLOGY; EPITHELIUM; LYMPHOCYTE; MONONUCLEAR CELL; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; SALIVA; SALIVARY GLAND DUCT; SECRETION (PROCESS); SECRETION RATE; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME;

ANIMALS; DISEASE MODELS, ANIMAL; EPITHELIUM; FEMALE; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SALIVA; SALIVARY DUCTS; SECRETORY RATE; SJOGREN'S SYNDROME; SUBMANDIBULAR GLAND; TOLL-LIKE RECEPTOR 9;

EID: 84911375834     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12209     Document Type: Article

References (29)

1. Venables PJ. Management of patients presenting with Sjogren's syndrome. Best Prac Res Clin Rheumatol 2006; 20: 791-807.
2. Hansen A, Lipsky PE, Dorner T. Immunopathogenesis of primary Sjogren's syndrome: implications for disease management and therapy. Curr Opin Rheumatol 2005; 17: 558-65.
3. Fox RI. Sjögren's syndrome. Lancet 2005; 366: 321-31.
4. Rasmussen A, Ice JA, Li H, et al. Comparison of the American-European Consensus Group Sjogren's syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort. Ann Rheum Dis 2014; 73: 31-8.
5. Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance cohort. Arthritis Care Res 2012; 64: 475-87.
6. Takei M, Shiraiwa H, Azuma T, et al. The possible etiopathogenic genes of Sjogren's syndrome. Autoimmun Rev 2005; 4: 479-84.
7. Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA 2006; 103: 2770-5.
8. Li J, Wang X, Zhang F, et al. Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases. Pharmacol Ther 2013; 138: 441-51.
9. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511.
10. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-5.
11. Savarese E, Chae OW, Trowitzsch S, et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 2006; 107: 3229-34.
12. Means TK, Latz E, Hayashi F, et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005; 115: 407-17.
13. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3: 745-56.
14. Dodeller F, Schulze-Koops H. The p38 mitogen-activated protein kinase signaling cascade in CD4 T cells. Arthritis Res Ther 2006; 8: 205.
15. Dominguez C, Powers DA, Tamayo N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel 2005; 8: 421-30.
16. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009; 60: 1232-41.
17. Zheng L, Zhang Z, Yu C, et al. Expression of Toll-like receptors 7, 8, and 9 in primary Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109: 844-50.
18. Zheng L, Zhang Z, Yu C, et al. Association between IFN-alpha and primary Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 107: e12-8.
19. Willeke P, Schotte H, Schluter B, et al. Interleukin 1beta and tumour necrosis factor alpha secreting cells are increased in the peripheral blood of patients with primary Sjogren's syndrome. Ann Rheum Dis 2003; 62: 359-62.
20. Greenspan JS, Daniels TE, Talal N, et al. The histopathology of Sjogren's syndrome in labial salivary gland biopsies. Oral Surg, Oral Med, Oral Pathol 1974; 37: 217-29.
21. Nakamura H, Kawakami A, Yamasaki S, et al. Expression of mitogen activated protein kinases in labial salivary glands of patients with Sjogren's syndrome. Ann Rheum Dis 1999; 58: 382-5.
22. Ping L, Ogawa N, Zhang Y, et al. p38 mitogen-activated protein kinase and nuclear factor-kappaB facilitate CD40-mediated salivary epithelial cell death. J Rheumatol 2012; 39: 1256-64.
23. Cha S, Peck AB, Humphreys-Beher MG. Progress in understanding autoimmune exocrinopathy using the non-obese diabetic mouse: an update. Crit Rev Oral Biol Med 2002; 13: 5-16.
24. Chiorini JA, Cihakova D, Ouellette CE, et al. Sjogren syndrome: advances in the pathogenesis from animal models. J Autoimmun 2009; 33: 190-6.
25. Cha S, Nagashima H, Brown VB, et al. Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjogren's syndrome) on a healthy murine background. Arthritis Rheum 2002; 46: 1390-8.
26. Robinson CP, Yamachika S, Bounous DI, et al. A novel NOD-derived murine model of primary Sjogren's syndrome. Arthritis Rheum 1998; 41: 150-6.
27. Lindqvist AK, Nakken B, Sundler M, et al. Influence on spontaneous tissue inflammation by the major histocompatibility complex region in the nonobese diabetic mouse. Scand J Immunol 2005; 61: 119-27.
28. Ridgway WM, Peterson LB, Todd JA, et al. Gene-gene interactions in the NOD mouse model of type 1 diabetes. Adv Immunol 2008; 100: 151-75.
29. Yamano S, Atkinson JC, Baum BJ, et al. Salivary gland cytokine expression in NOD and normal BALB/c mice. Clin Immunol 1999; 92: 265-75.